Navigation Links
Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results
Date:6/11/2009

ical need. There are more than 300,000 MRI procedures conducted in the U.S. and Europe each year that could benefit from the use of RG1068.

RG2417 for Bipolar Disorder

We are currently enrolling a Phase 2b clinical trial of RG2417, an oral formulation of uridine, in patients with bipolar depression. This is a multi-center, randomized, double-blind, placebo-controlled clinical trial in which approximately 150 patients with bipolar depression will receive either RG2417 or a placebo twice a day for eight weeks. The study is designed to assess the safety and efficacy of RG2417 on the symptoms of depression as measured by the Montgomery-Asberg Depression Rating Scale (MADRS) and the Clinical Global Impression of Change in Bipolar Disorder scale (CGI-BP-C). The design of the ongoing study is based on the positive results of a Phase 2a study in which 83 patients received either RG2417 or a placebo twice a day for six weeks. Over the six-week treatment period, the study demonstrated a statistically significant improvement in the symptoms of depression in the patients receiving RG2417 when compared to placebo on the MADRS (p=0.01) and the CGI-BP-C (p=0.04). In March, Repligen exclusively licensed worldwide rights to a patent application from McLean Hospital for the use of uridine in the treatment of patients with bipolar disorder. If issued, the patent would remain in force until at least 2025. More than two million adults in the U.S. have bipolar disorder.

HDAC Inhibitors for Friedreich's Ataxia and Huntington's Disease

We are currently developing inhibitors of histone deacetylases (HDACs) for the treatment of inherited neurodegenerative diseases such as Friedreich's ataxia and Huntington's disease. Preclinical studies have shown that HDAC inhibitors have the potential to arrest disease progression in Friedreich's ataxia, a novel approach to treating this debilitating disease. We have identified sever
'/>"/>

SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2009 Results
2. Repligen to Present at the Cowen and Company 29th Annual Healthcare Conference Monday, March 16th, 2:25 p.m. EDT
3. Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
4. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
5. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
6. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
7. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
8. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
9. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
10. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
11. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... (PRWEB) July 30, 2014 LayerBio, Inc., ... completion of its first round of seed financing from ... enable preliminary efforts to develop a novel sustained-release product ... of our investors and their commitment to this important ... LayerBio. "Ophthalmology is one of many areas in which ...
(Date:7/29/2014)... technologists have hurdled a number of significant technological ... revolutionary observing technology originally created for the James ... Principal Investigator Harvey Moseley, a scientist at NASA,s ... demonstrated that electrostatically actuated microshutter arrays that ... are as functional as the current technology,s ...
(Date:7/29/2014)... JOLLA, Calif. , July 29, 2014 ... diagnostic and therapeutic company focused on extending the healthy, ... hired Franz Och , Ph.D., an expert in ... Data Scientist. Och comes to HLI from Google where ... Google Translate. He will report directly to HLI Co-Founder ...
(Date:7/29/2014)... researchers has created a new way of manufacturing ... surfaces, made by self-assembly of carbon nanotubes, could ... controllable mechanical stiffness and strength, or the ability ... "We have demonstrated that mechanical forces can be ... microstructures, and that we can independently control ...
Breaking Biology Technology:Revolutionary microshutter technology hurdles significant challenges 2Revolutionary microshutter technology hurdles significant challenges 3Revolutionary microshutter technology hurdles significant challenges 4Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 2Franz Och, Ph.D., Expert in Machine Learning and Machine Translation, Joins Human Longevity, Inc. as Chief Data Scientist 3A new way to make microstructured surfaces 2
... COLUMBIA, Md., Oct. 16 Martek announced today,that ... of the former,stockholders of OmegaTech in ongoing litigation ... included in the,April 2002 merger agreement. In connection ... Martek common stock to the former stockholders of,OmegaTech, ...
... Bioponic,Phytoceuticals, Inc. (OTC: BPYT) ("Bioponic"), an ... serving the Complementary,Alternative Medicine (CAM) and nutraceutical ... Sales and Marketing of Southern California as ... including the states,of California, Washington, Nevada, Arizona, ...
... Full Range of Fertility Services and Surgeries, ... Dr. John Jain, a,fertility specialist with one ... announced today the grand opening of Santa ... health center in Santa,Monica, California. The center ...
Cached Biology Technology:Martek Announces Settlement of OmegaTech Milestone Litigation 2Bioponic Phytoceuticals to Roll Out Multiple Products to 1,000 Major Health Food Stores in the Western United States 2Pioneer in Reproductive Medicine Opens The Country's First Comprehensive Fertility Practice 2
(Date:7/28/2014)... United States have a circulatory problem of the legs ... may even require surgery in serious cases. This disease ... turn, limb amputation. , At The University of Texas ... tested a non-surgical preventative treatment in a mouse model ... blood circulation. Their proof-of-concept study appears in the ...
(Date:7/28/2014)... Fifteen years ago, MIT professor John Essigmann and colleagues from ... HIV drug. They thought if they could induce the virus ... eventually die out a strategy that our immune system ... a drug, which caused HIV to mutate at an enhanced ... from patients in a small clinical trial reported in 2011. ...
(Date:7/28/2014)... rat brain cells suggests that the effects of a ... cells are temporary. , The study, published in this ... was conducted by biologists at the University of California, ... York in response to concerns, arising from multiple studies ... to general anesthetics may increase their susceptibility to long-term ...
Breaking Biology News(10 mins):Scientists discover genetic switch that can prevent peripheral vascular disease in mice 2Forced mutations doom HIV 2Forced mutations doom HIV 3Forced mutations doom HIV 4Study suggests disruptive effects of anesthesia on brain cell connections are temporary 2Study suggests disruptive effects of anesthesia on brain cell connections are temporary 3
... have made a discovery that may explain how prion diseases, ... order to spread between various types of animals., The research ... change in the prions, makeup appears to give the disease ... strains with which it comes into contact. The team has ...
... what they eat, and whether horse meat might have ... headlines globally - calling for new policies in ... identification and authentication. As companies and manufacturers resort to ... public, it is estimated that up to 7% of ...
... March 11, 2013  Wake Forest Baptist Medical Center ... commercialization enterprise, Wake Forest Innovations, as well as ... Wake Forest Innovation Quarter After consultation ... and an analysis of park names worldwide, Piedmont ...
Cached Biology News:Discovery may explain how prion diseases spread between different types of animals 2DNA barcoding alone sufficient to detect fraudulent deer products 2DNA barcoding alone sufficient to detect fraudulent deer products 3Wake Forest Innovations Launches New Dot-Com Companies Offering Industry and Business Easy Access to Broad Range of Scientific Services 2Wake Forest Innovations Launches New Dot-Com Companies Offering Industry and Business Easy Access to Broad Range of Scientific Services 3Wake Forest Innovations Launches New Dot-Com Companies Offering Industry and Business Easy Access to Broad Range of Scientific Services 4Wake Forest Innovations Launches New Dot-Com Companies Offering Industry and Business Easy Access to Broad Range of Scientific Services 5
RABBIT ANTI RAT AQUAPORIN 5...
... 2.0 mL samples for freezing point determinations. Includes built-in printer, keypad, and ... optional scanner. RS-232 port. Microprocessor-controlled autocalibration. Two-step Calibration. ... ... ...
MAb to Hu-IFN-Gamma RC2 (CD118), NON-Neutralizing, Clone MMHGR-2 Binds to but does not neutralize human interferon gamma receptor...
Recombinant Rat CINC-2 alpha, CF...
Biology Products: